慢性丁型肝炎长期临床结局:持续病毒血症的作用
西班牙四中心回顾性队列纳入118例代偿期慢性丁型肝炎患者,中位随访8年。
要点
- 初始HDV-RNA可检出者肝硬化与肝失代偿风险显著更高
- 基线事件预测评分可分层临床事件风险(6%、25%、80%)
- 干扰素治疗减少肝失代偿,即使无病毒学应答
核心结论
- 持续HDV-RNA阳性者临床事件预后更差
- 基线事件预测评分有助于预测肝失代偿和肝细胞癌风险
- 干扰素可减少肝失代偿,即使无病毒学应答
研究设计与样本
- 西班牙四家学术医院的多中心研究
- 纳入抗-HDV阳性且代偿期肝病、随访≥12个月的患者118例
- 2888例HBsAg阳性者中151例(5.2%)抗-HDV阳性
主要发现
- 118例中58%为男性,中位年龄49岁,73%HDV-RNA可检出,30%有肝硬化
- 死亡率为0.44/1000人月
- 基线事件预测评分对应的临床事件概率分别为6%、25%、80%
临床怎么用
- 对慢性丁型肝炎患者应检测HDV-RNA以评估预后
- 可用基线事件预测评分对患者进行风险分层
- 干扰素治疗可能减少肝失代偿,即使未获病毒学应答
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis delta is a severe liver disease with rapid progression to cirrhosis. The impact of hepatitis delta virus (HDV)-RNA on disease progression and interferon treatment in a real-world cohort has been barely explored. AIM: To assess the development of clinical events in a cohort of chronic hepatitis delta patients according to the presence or absence of HDV-RNA METHODS: Multicentre study at four academic hospitals in Spain included anti-HDV-positive patients with compensated liver disease with a follow-up ≥12 months. RESULTS: Among 2888 HBsAg-positive subjects, 151 (5.2%) tested positive for anti-HDV, and 118 were included (58% men; median age, 49 years; 73% detectable HDV-RNA and 30% cirrhosis, most often in subjects with HDV-RNA). After a median follow-up of 8 years, subjects with initially detectable HDV-RNA were more prone to developing cirrhosis (31% vs 0%, P = .002) and/or liver decompensation (28% vs 3%, P = .019). Mortality rate was 0.44 per 1000 person-months. The probability of a clinical event was 6%, 25%, and 80% according to initial baseline-event-anticipation score. HDV-RNA became undetectable in 21 (24%) subjects either due to interferon or spontaneously (48% vs 52%, P = .29). Liver decompensation was reduced in interferon-treated patients (13% vs 38%, P = .026). CONCLUSIONS: Subjects with persistently positive HDV-RNA had a worse prognosis in terms of clinical events. Baseline-event-anticipation score is useful in predicting the risk of developing liver decompensation and hepatocellular carcinoma. Interferon was beneficial in reducing liver decompensation, even in the absence of virological response.
引用
- Palom A, Rodríguez-Tajes S, Navascués CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Aliment Pharmacol Ther. 2019. PMID: 31721254. doi:10.1111/apt.15521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。